PAA9 THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON INHALED CORTICOSTEROID EXPENDITURES AND USE  by Fung, V et al.
A334 Abstracts
PAA6
VALUING REDUCED RATES OF OROPHARYNGEAL ADVERSE
EVENTS: COMPARISON OF CICLESONIDE WITH
FLUTICASONE PROPIONATE
Wlodarczyk JH1, Harvey C2, Caeser M3
1John Wlodarczyk Consulting Services, New Lambton, NSW,
Australia, 2Altana Pharma Pty Ltd, NOrth Ryde, NSW, Australia,
3ALTANA Pharma AG, Konstanz, Germany
OBJECTIVES: Inhaled corticosteroids can cause oropharyngeal
adverse events (OAEs). We investigated the direct costs of treat-
ing oral candidiasis and hoarseness OAEs in Australia (costs
$AUD). METHODS: We assumed 4% fewer OAEs in patients
treated with ciclesonide (CIC), compared to ﬂuticasone propi-
onate (FP), based on data from a 12-week, randomized, double-
blind clinical trial in patients with moderate asthma (comparable
efﬁcacy; OAE rate: CIC [400 μg/day] 0.5%; FP [500 μg/day]
4.5%; rate difference (RD) 4%, 95% CI: 1.04%–6.95%). Cost-
ings were done based on resource sparing and resource intensive
assumptions. RESULTS: The resource sparing model assumed:
1.9 doctor visits ($30.85 per visit) and 1.9 nystatin treatments
($9.08 per treatment) to diagnose and treat OAE. The estimated
treatment cost per OAE was $75.87. The average cost saving per
patient treated with CIC per 12-week period was $3.03 ($75.87
× 4%). The cost saving per prescription with CIC per 12-week
period was $2.02 ($3.03/1.5). Sensitivity analyses showed
savings per prescription of $0.53 to $3.52 (using lower and
upper 95% CI for OAE RD). The resource intensive model
assumed: 3.4 doctor visits ($30.85 per visit) and 3.4 nystatin
treatments ($9.08 per treatment) to diagnose and treat OAE; 
1.0 specialist visit ($72.60) and 1.0 ketoconazole treatment
($38.58). The estimated treatment cost per OAE was $246.94.
The average cost saving per patient treated with CIC per 12-
week period was $9.88 ($246.94 × 4%). The cost saving per pre-
scription with CIC per 12-week period was $6.59 ($9.88/1.50).
Sensitivity analyses showed savings per prescription of $1.71 to
$11.44 (using lower and upper 95% CI for OAE RD). CON-
CLUSIONS: We believe the improved safety proﬁle of CIC
would reduce resource use associated with treating OAEs and
have favorable long-term clinical and economic outcomes.
PAA7
ANALYZING THE INFLUENCE OF SWITCHING BETWEEN
DIFFERENT ASTHMA REGIMES ON MEDICATION ADHERENCE
TO ASTHMA THERAPY, RESOURCE UTILIZATION AND COSTS
Buesch K1,Welte R2, Singer C2
1GSF-National Research Center for Environment and Health,
Neuherberg, Bavaria, Germany, 2GlaxoSmithKline, Munich, Germany
OBJECTIVE: The study was undertaken to examine the impact
of medication adherence on health care utilization and costs. 
In sub-analyses the differences between patients who switch
between different regimes or agents compared to those, who con-
tinuing to take their existing medication were analysed.
METHOD: This retrospective observational study included
1459 patients (°Y´18) with asthma. From January 2001 through
December 2004, the medication possession ratio (MPR)was used
to assess adherence. Data on resource utilization including physi-
cian visits and hospital referrals was collected. Unit costs at 2005
prices were applied to this data to estimate the mean annual costs
per patient. Indirect costs due to workdays lost were also con-
sidered. RESULTS: Of 1459 patients who are under anti-asth-
matic therapy, 300 were taking an inhaled long-acting beta2
agonist (LABA), 278 patients an inhaled corticosteroid (ICS) and
94 patients were using both (LABA + ICS). Another 457 and 424
patients were receiving the ﬂuticasone/salmeterol and budes-
onide/formoterol ﬁxed combination, respectively. About 30% of
the patients switch between inhaled medications. This cohort
showed a higher mean adherence (62%) compared to the
patients continuing to take their existing inhaler (56%). Also the
proportion of patients achieving an adequate adherence level was
higher (46% versus 39%). However, compared with the patients
who stick to their medications, those who switch between
regimes or agents had more unscheduled physician visit (1,9 per
switching vs. 1,59 per existing patient) and more work-loss days
(14,1 days per switching vs. 6,34 days per existing patient).
When comparing both the direct costs and indirect costs, switch-
ing patients caused higher costs per patient. CONCLUSIONS:
Even though the patients who switch show a better adherence
with their treatment, they cause higher mean direct and indirect
costs per patient per observation year. This ﬁnding indicates that
it might be better to adjust patients successfully to one product.
PAA8
A COMPARISON OF CLAIMS RATIO BETWEEN PRIMARY AND
SECONDARY DRUGS IN THE MANAGEMENT OF ASTHMA. A
CANADIAN ANALYSIS
Ciobanu A
AstraZeneca, Mississauga, ON, Canada
OBJECTIVES: To compare the use of secondary drugs (SABA-
Short acting beta adrenergic agents, formoterol fumarate dihy-
drate and formoterol fumarate) correlated to the use of primary
drugs (ﬂuticasone/salmeterol and budesonide/formoterol combi-
nation as a single inhaler), using a claims ratio measurement unit,
in the management of asthma. METHODS: A retrospective
analysis has been conducted using a Canadian health care insur-
ance claims database. In order to obtain the claims ratio unit,
the database review analysed the number of patients (claimants)
that used the above-mentioned medication. The main criteria for
selecting the claimants were: Patients with at least 2 claims for
one of the main target drugs during the index period. Active
patients: who had a claim for any drug at least 6 months before
and 12 months after their ﬁrst claim of the target drug during
the index period. Patients that did not switch therapy between
the main target drugs during the index period. The perspective
was of the third party payer. RESULTS: The use of budes-
onide/formoterol combination as a single inhaler as a primary
drug in the management of asthma, determined a decrease in the
number of claims and use of secondary drugs (one claim of
budesonide/formoterol combination as a single inhaler deter-
mined 0.71 claims of fenoterol HBR vs. 0.86 with ﬂuticasone/sal-
meterol vs. 1.28 with budesonide, and vs. 0.92 with ﬂuticasone
propionate), formoterol fumarate dyhidrate (0.53 vs. 0.59 vs.
1.16 vs. 0.95), and formoterol fumarate (0.44 vs. 0.47 vs. 1.43
vs. 0.83). The claims analysis shows a decrease in the claims ratio
and costs of secondary drugs and overall treatment costs when
using budesonide/formoterol combination as a single inhaler.
CONCLUSIONS: The budesonide/formoterol combination as a
single inhaler can represent an economically advantageous
asthma treatment option compared with other primary drugs.
PAA9
THE EFFECTS OF GENERIC-ONLY DRUG COVERAGE ON
INHALED CORTICOSTEROID EXPENDITURES AND USE
Fung V1, Fireman B1, Brand R2, Newhouse JP3, Hsu J1
1Kaiser Permanete, Oakland, CA, USA, 2University of California at San
Francisco, San Francisco, CA, USA, 3Harvard University, Boston, MA,
USA
OBJECTIVE: Generic-only drug-beneﬁt coverage is increasingly
common. There are no generic inhaled corticosteroids (ICS),
therefore, patients with generic-only coverage pay full-price for
ICS drugs. We examined the impact of losing brand-coverage on
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ICS expenditures and use (2003–2004) among Medicare+Choice
beneﬁciaries with asthma, and a high-severity asthma subgroup.
METHODS: We used automated data from an integrated deliv-
ery system in the U.S. All subjects were continuously enrolled,
age 65+, asthma-registry members with prior ICS use, and had
$10 generic-copayments and no chronic obstructive pulmonary
disorder diagnoses or ipratropium bromide use (n = 2,908). In
2004, 74.0% switched from a $30 brand-copayment with a
$1000 annual cap, to generic-only coverage (full-price for brand-
drugs), with no cap; 26.0% had $15–25 brand-copayments
2003–2004 (control-group). We used linear difference-in-differ-
ence models to examine changes (2003–2004) in ICS expendi-
tures (total and out-of-pocket) and use (days-of-supply). Models
adjusted for gender, age, race/ethnicity, neighborhood socioeco-
nomic-status, comorbidity, chronic diseases, and asthma 
characteristics (high-risk asthma-ﬂag, high-dose ICS, prior
asthma-related emergency or hospital visits, oral steroid use, and
ICS type). We deﬁned patients as having high-severity asthma if
they had a high-risk ﬂag or a high-dose ICS prescription (n =
798). RESULTS: In multivariate analyses, patients who lost
brand-coverage had lower total ICS expenditures (−$106,
[95%CI: −$125 to −$87]), but higher out-of-pocket expenditures
($52, [$40 to $64]), compared with patients with no coverage
changes; ICS days-of-supply were also lower (−11.6 days, [−18.5
to −4.8]). Among high-severity asthma patients, loss of brand-
coverage was associated with changes similar in direction, but
larger in magnitude: total ICS expenditures (−$270, [−$322 to 
−$219]); out-of-pocket expenditures ($74, [$43 to $104]); and
days-of-supply (−24.2, [−37.6 to −10.9]). CONCLUSIONS:
Patients with generic-only coverage had higher out-of-pocket
costs and lower total expenditures and days-of-supply for
inhaled corticosteroids. These changes were greater among high-
severity asthma patients. Future research will examine the clini-
cal effects of these changes.
PAA10
HEALTH PLAN STRUCTURE AND EXPENDITURES FOR
ASTHMA CARE
Nurmagambetov T,Atherly A,Williams S, Redd S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: The objective of this study is to evaluate the effect
of health plan structure on health care utilization and expendi-
tures for asthma care. Some health plans in the USA require a
designated primary care physician (PCP plans) and some do not
(NPCP plans). METHODS: Our data was drawn from the
MEDSTAT MarketScan database. The sample had 330,685
patients with either at least one hospitalization or at least two
outpatient visits for asthma during 1998–2001. Approximately
47% (154,106) of the patients had PCP plans; the remainder had
NPCP health plans. We performed regression analysis to
examine the effect of having a primary care physician and capi-
tation in the health plan on expenditures for asthma, controlling
for gender, age, employment status, and health status via the
Charlson comorbidity index. RESULTS: We found annual per
capita inpatient expenditures for asthma were about 8.4% lower
for the patients in the PCP plans compared to the patients in the
NPCP plans (p < 0.01), with a mean length of stay 0.07 days
shorter (p < 0.01) and 0.02 times fewer admissions (p < 0.01)
per year for asthma. However, annual per capita outpatient
expenditures for asthma were 9.1% higher in the PCP plans com-
pared to the NPCP plans (p < 0.01) as PCP asthma patients
received 1.4 more outpatient services per year (p < 0.01) and
about 0.2 more outpatient visits (p < 0.01) per year than NPCP
asthma patients. On net, total expenditures were 3.2% lower for
PCP asthma patients (p < 0.01) than for NPCP asthma patients.
CONCLUSIONS: For asthma care, there is a tradeoff between
relatively inexpensive outpatient services and more expensive
inpatient services. Results of this study suggest that patients with
asthma enrolled in PCP plans used signiﬁcantly more outpatient
services and fewer inpatient services, resulting in lower overall
spending.
PAA11
COST-EFFECTIVENESS ANALYSIS FOR THE ASSESSMENT OF
PREVENTIVE SCHEMES BASED ON GENETIC SCREENING
Gutierrez de Mesa E1, Hidalgo I2, Christidis P2, Ciscar JC2,Vegas E3,
Ibarreta D2
1Institute for Prospective Technological Studies, JRC-European
Commission, Seville, Spain, Spain, 2Institute for Prospective
Technological Studies, JRC-European Commission, seville, Spain, Spain,
3Servicio Madrleño de Salud, Alcala de Henares. MADRID, Spain
OBJECTIVE: The study is focused on the potential impacts of
genome-based technologies on health care. We have chosen
asthma in children as a case study and gene-screening as the tech-
nology assessed to explore the cost-effectiveness of applying an
early genetic- screening to newborns and a preventive treatment
to the population at risk. METHODS: A Markov model con-
sisting on six mutually exclusive disease states with a simulation
horizon of 100 years was constructed. Two different scenarios
were deﬁned. RESULTS: In the base case and for scenario 1, the
number of quality adjusted life years (QALY) gained is 4.081
and the incremental cost-effectiveness ratio per QALY gained is
€40416.1/QALY. In scenario 2, the number of QALYs gained is
1.483 and the incremental cost-effectiveness ratio per QALY
gained falls to €18474.27/QALY. We have carried out a sensi-
tivity analysis varying the discount rate, the cost of genetic
testing and considering two different transition matrixes for the
preventive programme. Two main conclusions are derived from
the sensitivity analysis carried out. Firstly, it seems that increas-
ing by 2% the discount rate for both cost and health outcomes
the cost-effectiveness of the preventive programme does not vary
so much. However, discounting costs and beneﬁts at 5% the pre-
ventive programme in both scenarios appears as cost-effective.
Secondly, it seems that increasing the cost of genetic testing up
to 100€ the cost-effectiveness of the preventive programme in
both scenarios remains practically stable. CONCLUSIONS: The
cost-effectiveness of an early genetic-screening and the preven-
tive strategy applied to all populations presenting the selected
ADAM33 remains at the limit of the cost-effectiveness. Never-
theless the model represents a valuable tool to prospectively
assess cost-effectiveness of preventive schemes based on genetic
screening.
PAA12
THE EFFECT OF SWITCHING ON ADHERENCE TO
DIFFERENT TYPES OF ASTHMA TREATMENT
Buesch K1, Singer C2,Welte R2
1GSF-National Research Center for Environment and Health,
Neuherberg, Bavaria, Germany, 2GlaxoSmithKline, Munich, Germany
OBJECTIVES: Medication adherence rates (using the MPR)
were assessed among asthmatic patients who are under therapy
with an inhaled long-acting beta2-agonist + corticosteroids
(LABA+ICS) or a ﬁxed ﬂuticasone/salmeterol combination
(FSC).The differences between patients, who stick to their
therapy, compared to those, who switch between different
regimes or agents were analysed. METHODS: Claims data were
drawn from the IMS Database. Patients with asthma (°Y´18
years) who are under inhaled therapy according to the National
